Lonza confident on 2022 targets as H1 sales deliver healthy growth

By Joshua Kirby

 

Lonza Group AG confirmed its financial outlook for this year on Friday, as sales and profits rose sharply in the first half of 2022 on strong consumer demand.

Sales totaled 2.98 billion Swiss francs ($3.08 billion) in the six months, up 17% from 2.54 billion Swiss francs in the same period last year, a indicated the Swiss society of life sciences. Basic earnings before interest, taxes, depreciation and amortization meanwhile increased by 16.5% to CHF 987 million, with a slight contraction in the margin to 33.1%.

Good demand in divisions such as biologics and the cells and genes business helped drive sales growth in the six months, Lonza said.

Looking ahead, Lonza said it expects to achieve its teenage full-year sales growth outlook and improved Core Ebitda margin, in line with the medium-term guidance.

The biologics division will be boosted by investment in a new commercial fill and finish facility in the municipality of Stein, as previously announced, said general manager Pierre-Alain Ruffieux.

“This will help us meet customer demand for an integrated offering and bring long-term value to our business,” he said.

 

Write to Joshua Kirby at [email protected]; @joshualeokirby

 

(END) Dow Jones Newswire

July 22, 2022 01:35 ET (05:35 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

About Nicole Harmon

Check Also

Li’l Friday Roundup: Nate Bargatze, Five for Fighting, Library Book Sale

Five for Fighting and The Verve Pipe will perform at the Greenfield Lake Amphitheater on …